Janssen Pharmaceuticals has entered into a worldwide license and collaboration agreement with Cidara Therapeutics to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza. The deal, which is worth up to US$780 M, gives Janssen access to Cidara’s Cloudbreak® antiviral platform that generates AVCs with potent antimicrobial activity and immune system engagement in a single long-acting molecule. Interestingly, the deal comes seven months after Janssen terminated development of its Phase III influenza A treatment pimodivir following an interim analysis.